RenataFerrarottoMD

PubMed

• A prospective cohort study on stereotactic radiotherapy in the management of dural recurrence of olfactory neuroblastoma.
  Christopher D Goodman, Franco DeMonte, Theresa P Nguyen, Adam S Garden, Catherine He Wang
  Head & Neck. 2025-01-01
• Induction Chemotherapy for Sinonasal Tumors in Patients Presenting with Brain Invasion and/or Neurological Deficits.
  Bledi C Brahimaj, Kevin J Contrera, Franco Rubino, Romulo Andrade de Almeida, Renata Ferrarotto
  Journal of Neurological Surgery. Part B, Skull Base. 2024-12-01
• Phase II Trial of Induction Chemotherapy for Advanced Sinonasal Squamous Cell Carcinoma.
  Kevin J Contrera, Renata Ferrarotto, Brandon Gunn, Shirley Y Su, Merrill S Kies
  Clinical Cancer Research. 2024-11-12

Journal Articles

• Risk and Clinical Risk Factors Associated with Late Lower Cranial Neuropathy in Long-Term Oropharyngeal Squamous Cell Carcinoma Survivors  
  Ryan P Goepfert, Stephen Y Lai, Renata Ferrarotto, Erich M Sturgis, JAMA Otolaryngology–Head & Neck Surgery
• Evaluation of Overall Survival in Patients with Anaplastic Thyroid Carcinoma, 2000-2019  
  Renata Ferrarotto, MD, JAMA Oncology
• PI3‐Kinase Pathway Biomarkers in Oral Cancer and Tumor Immune Cells  
  Bonnie S Glisson, Jeffrey Myers, N Jr William, Renata Ferrarotto, Head & Neck
• Combining Immune Checkpoint Blockade and Tumor-Specific Vaccine for Patients with Incurable Human Papillomavirus 16–Related Cancer  
  Erminia Massarelli, William William, Ming Guo, Merrill Kies, Bonnie Glisson, Hai Tran, Faye Johnson, Renata Ferrarotto, Lei Feng, JAMA
• Join now to see all

Lectures

• ACCURACY: phase (P) 2 trial of AL101, a pan-Notch inhibitor, in patients (pts) with recurrent/metastatic (R/M) adenoid cystic carcinoma (ACC) with Notch activating mut... 
  2019 ASCO Annual Meeting - 6/1/2019
• Checkpoint inhibitors assessment in oropharynx cancer (CIAO): Safety and interim results. 
  2019 ASCO Annual Meeting - 6/1/2019
• Safety and interim results from a phase II, single-arm study of atezolizumab and bevacizumab in Merkel cell carcinoma (MCC). 
  2019 ASCO Annual Meeting - 6/1/2019
• Immuno-radiotherapy: A New Approach? Integrating Immunotherapy Into Standard of Care for Head and Neck Cancer 
  2018 ASCO Annual Meeting - Chicago, Illinois - 06/1/2018
• Join now to see all